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Edited by Takashi GojoboriAbstract Extracellular human immunodeﬁciency virus-1 (HIV-
1) Tat protein and Tat-derived peptides are biologically active
but mechanisms of Tat processing are not known. Within the
highly conserved basic region of HIV-1 Tat protein (amino acids,
a.a. 48–56), we identiﬁed two putative furin cleavage sites and
showed that Tat protein was cleaved in vitro at the second site,
RQRR# (a.a. 53–56#). This in vitro cleavage was blocked by a
monoclonal antibody that binds near the cleavage site or by the
furin inhibitor a-1 PDX. Monocytoid cells rich in furin also
degraded Tat and this process was slowed by the furin inhibitor
or the speciﬁc monoclonal antibody. Furin processing did not
aﬀect the rates for Tat uptake and nuclear accumulation in
HeLa or Jurkat cells, but the transactivation activity was greatly
reduced. Furin processing is a likely mechanism for inactivating
extracellular HIV-1 Tat protein.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The Tat protein of human immunodeﬁciency virus-1 (HIV-1)
is a transcriptional activator for the provirus. Sequence-speciﬁc
interactions of Tat proteinwith host factors and binding of these
complexes to the transactivation-responsive sequence element in
human immunodeﬁciency virus RNA relieve a block to tran-
script elongation and increase viral gene expression [1]. Tat is
present in sera from infected individuals [2] and in Kaposi’s
sarcoma lesions where it was associated with endothelial spindle
cells. Cells acutely infected with HIV supply Tat to cocultured
spindle cells and increase their growth rate [3]. Extracellular Tat
can rescue virus expression in some latently infected cells [4] and
increase the permissivity of monocytes and lymphocytes for
HIV-1 by increasing surface expression of the viral coreceptors,
CXCR4 [5] and CCR5 [6].
Peptides corresponding to the cysteine-rich domain of Tat
will activate monocytes [7] and induce tumor necrosis factor-
related apoptosis-induced ligand (TRAIL) – mediated CD4+
T-cell killing [8]. Peptides containing the basic domain stimu-
lated cytokine production in T-cells [9] and mediated protein
transduction in many cell types [10]. Clearly, fragments or
peptides from Tat retain a variety of activities, but whether
these peptides are released in vivo, and the mechanisms for
processing the intact protein, have not been described.* Corresponding author. Fax: +1-410-706-5198.
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quired for nuclear entry and transcription. We noted the
presence of recognition sites for furin-like endoproteases
within this part of the protein. Furin is expressed in a broad
range of tissue and cells, including T-cells and macrophages
[11], and endoproteolytic cleavage occurs at the carboxyl ter-
minus of the consensus sequence Arg-X-Lys/Arg-Arg#. Furin
cycles between the trans-Golgi network and the cell surface
[12], and is also active in conditioned medium [13]. Here, we
studied furin recognition and cleavage of HIV-1 Tat. We show
that Tat cleavage by furin occurs in the most conserved region
of the protein and furin-like proteases may be involved in
processing of Tat in vivo.2. Materials and methods
2.1. Monoclonal antibodies, Tat protein, and cell lines
Monoclonal antibodies that prevent nuclear accumulation and
neutralize extracellular Tat activity in T-cells were reported previously
[14]. The TR1 antibody binds to the amino terminal peptide (a.a. 1–15)
and the 9A11 antibody recognizes the epitope RPPQ at a.a. 57–60. Tat
protein (86 a.a.) from HIV BH10 was from Advanced Biosciences
Laboratory, Inc., Kensington, MD or Aventis Pasteur, Paris, France.
A full-length 101 a.a. Tat protein was from Xeptagen, S.p.A., Naples,
Italy. The monocytoid cell line J774A.1 was obtained from the ATCC
collection.
2.2. Incubation of extracellular Tat with J774A.1 cells
Examination of the HIV-1 Tat amino acid sequence revealed two
putative furin cleavage sites (a.a. 49–50# and a.a. 53–56#) within the
basic region. The myeloid J774A.1 cells are known to express furin on
the cell surface [11]. We incubated 106 J774A.1 cells in 50 ll of 0.15 M
NaCl with 20 mM HEPES, pH 7.4, and 3 mM Ca2þ with 15 ng of
recombinant Tat for diﬀerent periods of time at 37 C, in the presence
or absence of 8 lg/ml of furin-like protease inhibitor, a-1 antitrypsin
Portland (a-1 PDX). In some experiments, Tat was incubated with
J774A.1 cells in the presence of 2 lg of 9A11 antibody or IgG1 control
antibody. Cell free ﬂuids were collected, separated by gel electropho-
resis, and detected by Western blotting with the TR1 monoclonal
antibody.
2.3. In vitro cleavage of Tat protein
In most experiments, we used the recombinant 86 a.a. form of HIV
IIIB Tat. In some experiments, the 101 a.a. form of Tat was used. Tat
was incubated with furin (Aﬃnity Bioreagents, Golden, CO) at 1 lg of
Tat to 1 U of furin in 20 ll of 200 mM HEPES, pH 7.2, containing 3
mM Ca2þ, for 2 h at 37 C. Tat cleavage was prevented by a speciﬁc
inhibitor of furin, a-1 PDX [15] (Fig. 1B). Products of the Tat cleavage
were detected by either Coomassie staining of the polyacrylamide gel
or Western blotting with the monoclonal antibody TR1, that recog-
nizes the amino terminus.
2.4. NH2-terminal sequencing
The 56 a.a. amino terminal Tat fragment was isolated by reverse
phase HPLC on the Xterra MS C18 reverse phase column (Waters,ation of European Biochemical Societies.
Fig. 2. (A) Monoclonal antibody 9A11 blocks furin cleavage of Tat in
vitro. The 9A11 antibody recognizes the 57RPPQ60 sequence imme-
diately downstream from the second putative furin recognition site
(a.a. 53–56). (B) Tat degradation by J774A.1 cells was slowed in the
presence of antibody 9A11. (C) Within the Tat sequence a furin
cleavage site is indicated by arrow and the 9A11 epitope is highlighted
in bold type.
Fig. 1. (A) The furin inhibitor a-1 PDX slows Tat degradation in cell
culture. Tat degradation was reduced signiﬁcantly in the presence of a-
1 PDX (+) compared to controls without inhibitor ()). The results are
representative of three independent experiments. (B) Cleavage of Tat
(86 a.a., HIV-1 III B) by furin in vitro. Coomassie staining of the
polyacrylamide gel is shown. Furin treatment of Tat reduced the level
of full-length cleaved Tat (14 kDa) and generated two cleaved prod-
ucts. The reaction is inhibited by adding the speciﬁc furin inhibitor a-1
PDX. Lane 1: non-treated Tat, lane 2: furin-treated Tat, lane 3: inhi-
bition of Tat cleavage by a-1 PDX, lane 4: furin alone, lane 5: a-1 PDX
alone.
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of acetonitrile in 0.1% TFA. The truncated 56 a.a. Tat was present in
fractions containing 41–45% acetonitrile. Cleavage products were
separated in 16.5% Tris–Tricine polyacrylamide gels to isolate the C-
terminal Tat fragment. This fragment was submitted for sequencing by
Edman’s degradation (N-terminal sequencing) to conﬁrm the cleavage
site.
2.5. Tat internalization and Tat transactivation assays
Jurkat cells at 5 106 per ml were incubated with recombinant Tat
(86 a.a. ABL, Kensington, MD) at 1 lg/ml, in RPMI supplemented
with 0.1% Ultrapure BSA (Panvera, Madison, WI) for 1 h at 37 C. In
some cases, Tat was preincubated with monoclonal antibodies 9A11,
TR1 or IgG controls at the ratio of 1 lg Tat to 25 lg IgG. After
incubation, the cells were washed three times, then nuclear extracts
were prepared using NE-PER kit (Pierce, Rockford, IL). The trans-
activation assay used a HeLa T4 cell line, containing a Tat-deﬁcient
integrated provirus (HeLa T4 HIV Tat-minus cells) [16] and was
performed as described [14]. Brieﬂy, HeLa T4 HIV Tat-minus cells
were seeded into 96-well plates, at 20 000 cells per well, and incubated
overnight. The wells were then incubated for 90 min with diﬀerent Tat
concentrations in RPMI, containing 0.1% Ultrapure BSA (Panvera,
Madison, WI). The Tat solution was replaced with DMEM containing
10% FBS and 96 h later supernatants were tested for p24 content using
a commercial ELISA (R&D Systems). In some experiments, after in-
cubation with intact or furin-treated Tat HeLa T4 HIV Tat-minus
cells were lyzed and nuclear extracts were analyzed in Western blot
with monoclonal antibody TR1 to measure nuclear accumulation of
Tat.
2.6. Western blotting
Western blotting was performed as described previously [14]. Brieﬂy,
12.5 lg of each nuclear extract was separated by polyacrylamide gel
electrophoresis and transferred to a PVDF membrane. Protein transfer
eﬃciency was routinely controlled by membrane staining with PonceauRed (Sigma, St. Louis, MO). TR1 monoclonal antibody (0.5 lg/ml)
and subsequent goat anti-mouse alkaline phosphatase conjugate
(Sigma) were used to detect Tat on the blots.3. Results
3.1. Tat degradation in cell culture is slowed by a speciﬁc
inhibitor of furin-like proteases or a monoclonal antibody to
the basic domain of Tat
Tat protein is not internalized by monocytoid cells and is
degraded rapidly in culture. To test whether Tat cleavage may
be mediated by furin-like proteases, we incubated Tat with the
myeloid cell line J774A.1, that is known to express furin on its
surface [11]. Tat was incubated with J774A.1 for diﬀerent pe-
riods of time in the presence or absence of a-1 PDX, anti-Tat
antibody 9A11 or IgG1 control antibody.
Degradation of Tat was signiﬁcantly reduced by a-1 PDX,
(Fig. 1A) or Tat-speciﬁc 9A11 antibody (Fig. 2B). We could
not detect Tat accumulation in the cytoplasm or nuclei of
J774A.1 cells in agreement with our previous ﬁnding that up-
take of extracellular Tat is not detected in myeloid cells [8]. The
experiment was repeated three times with similar results.
3.2. Furin cleavage sites in HIV-1 Tat
Entropy plot analysis of more than 1300 Tat sequences
identiﬁed a highly conserved region between a.a. 44 and 56
[14]. This region includes a lysine/arginine rich sequence des-
ignated the basic domain [17]. Within the basic domain we
identiﬁed two putative furin cleavage sites. The predicted
Fig. 3. Uptake of non-cleaved and furin-cleaved Tat by Jurkat T-cells.
Both non-cleaved and cleaved Tat accumulated in the nuclei of Jurkat
cells as shown by Western blotting of nuclear extracts with the
monoclonal antibody TR1. TR1 recognizes an N-terminal part of Tat
and only binds the larger cleavage product. Both monoclonal anti-
bodies, TR1 (recognizing the N-terminal epitope) and 9A11 (recog-
nizing the 57RPPQ60 sequence), inhibit uptake of intact Tat. Antibody
TR1 but not the antibody 9A11 inhibited the uptake of cleaved Tat,
since the epitope for 9A11 is separated by the furin reaction from the
basic region sequences that control cellular penetration and nuclear
localization.
Fig. 4. (A) Inhibition of Tat transactivation activity by furin cleavage.
The furin-treated Tat (triangles) had a reduced capacity to activate the
Tat deﬁcient integrated HIV provirus compared to mock-treated Tat
(squares). Data are expressed as meansS.D. of the optical density
readings from quadruplicate capture ELISA assays. (B) Both intact
and furin cleaved. Tat accumulate in the nuclei of HeLa T4 HIV Tat-
minus cells in similar manner, as determined by Western blotting of
nuclear lysates.
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53–56/57. Importantly, these sites are highly conserved in all
HIV-1 sequences including multiple clades, and the second site
(53–56/57) abuts the epitope for our 9A11 monoclonal anti-
body at a.a. 57–60 [14].
3.3. Furin cleaves Tat in vitro
Commercial 86 a.a. Tat was incubated with a puriﬁed furin.
The cleavage produced two fragments of Tat (Fig. 1B) corre-
sponding approximately to 7 and 5 kDa portions. Cleavage
eﬃciency was routinely around 70%, although a minor fraction
of non-cleaved material always remained. This may be due to
the interaction between Tat molecules [18] or conformational
changes that inhibit enzyme access to the cleavage site.
Cleaved Tat was puriﬁed by reverse phase HPLC and then
subjected to electrospray mass spectrometry. The mass spec-
trometry identiﬁed a larger fragment of 6.6 kDa, that corre-
sponds to cleavage at the second putative site, 53RQRR/R57.
To conﬁrm the cleavage site assignment, we separated frag-
ments with a 16.5% Tris–Tricine polyacrylamide gel, then
eluted the small fragment (carboxy terminal fragment) for
Edman’s degradation sequencing. The sequencing conﬁrmed
that cleavage occurred at the second putative furin site, placing
the scissile bond between a.a. 56 and 57. We have also con-
ﬁrmed that furin cleaves full-length (101 a.a.) Tat protein be-
tween a.a. 56 and 57; irrespective of sequence diﬀerences at a.a.
57.
3.4. Monoclonal antibody 9A11 inhibits Tat cleavage by furin
The furin cleavage site in Tat abuts the minimal recognition
site for our neutralizing monoclonal antibody 9A11 (a.a. 57–
60). We next tested whether this monoclonal antibody would
speciﬁcally block furin-mediated cleavage.
Tat protein was incubated with monoclonal antibody 9A11
or the control monoclonal antibody TR1 that recognizes the
amino terminus. These complexes were exposed to furin and
cleavage was monitored by polyacrylamide gel separation of
products followed by Western blotting with the amino-termi-
nal speciﬁc detection antibody TR1. Furin cleavage was
blocked by 9A11 but not by the amino terminus-speciﬁc TR1
monoclonal antibody (Fig. 2A).
3.5. Uptake of the Tat protein by Jurkat cells and inhibition by
monoclonal antibodies
We showed previously that exogenous Tat added to Jurkat
T-cells readily enters and translocates to the nucleus [14].
This process was blocked by preincubating Tat with mono-
clonal antibody TR1 (reacting with an epitope within a.a.
1–15) or 9A11 (recognizing amino acids sequence 57–60).
Here, we showed that the amino terminal Tat fragment
generated by furin cleavage readily enters cells and penetrates
the nucleus, similarly to 86 a.a. Tat (Fig. 3). The 9A11 an-
tibody does not inhibit uptake of the furin-truncated form of
Tat, because the antibody epitope is destroyed by the
cleavage reaction (Fig. 3).
3.6. Furin cleavage reduces Tat activity in a cell-based
transactivation assay
We asked whether furin cleavage altered the biological ac-
tivity of Tat protein. Tat was treated with furin for 2 h at 37 C
and tested in the transactivation assay. Sequential 1:1 dilutions
of cleaved Tat were tested for their ability to induce p24 pro-duction in HeLa T4 HIV Tat-minus cells. As a control, Tat
was incubated in buﬀer without furin for 2 h at 37 C and then
overlayed on the indicator cells. Furin-treated Tat had a
markedly reduced transactivation activity that was decreased
approximately eight times compared to mock-treated controls
(Fig. 4A). Furin cleavage reduced the transactivation activity
of Tat without preventing Tat uptake and entry into the nu-
cleus (Fig. 4B).
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The primary function of Tat is to regulate transcription from
the HIV long terminal repeat. However, other evidence sug-
gests that extracellular Tat contributes to HIV disease through
its eﬀects on bystander cells but mechanisms for eliminating
extracellular Tat are not known. We showed that furin present
on cell surfaces or in conditioned medium participates in the
proteolytic processing of HIV-1 Tat. In vitro assays mapped
the cleavage site to the second of two possible positions and
showed that furin cleavage was not aﬀected by Tat sequence
variation at the carboxyl-terminus proximal position in the
recognition site. Furin cleavage signiﬁcantly reduced Tat
protein potency for transactivating virus expression.
There is little information in the literature about post-
translational modiﬁcations or processing of Tat. It is known
that acetylation of lysines 50 and 51 stimulates Tat transcrip-
tional activity [19]. Recently, the ﬁrst report on Tat proteolytic
processing showed that the HIV-1 protease was capable of
degrading this protein in vitro [20]. We showed that Tat is
degraded by contact with monocytoid cells and the process
involves furin proteases in addition to other cellular proteases.
In vitro studies conﬁrmed that Tat protein can be cleaved by
furin, a subtilisin-like, Ca2þ-dependent endoprotease expressed
in many eukaryotic cell types. Furin recognition at a.a. 52–56
matched the consensus recognition sequence (Arg-X-Lys/Arg-
Arg#) that is also recognized by a family of kexin/subtilisin-
like serine proteinases (so-called convertases) found in many
cells and tissues. The family of proteases includes furin, PC1/3,
PC2, PACE4, PC4, PC5/6, PC7/LPC, PACE4, PC5/6 and PC7/
LPC that are widely distributed among tissue and cell types
[11]. So far, we have only tested furin in the Tat cleavage
system but other family members may also be active.
Analysis of Tat sequences obtained from the NCBI database
showed that a.a. 43–56, corresponding to the basic domain of
Tat, are highly conserved among diﬀerent HIV isolates [14].
This sequence is known to be important for Tat biological ac-
tivity and represents an important target for the development
of therapeutic agents. However, we found recently that this
amino acid sequence is poorly immunogenic compared with
non-conserved downstream sequences or the amino terminus
(Tikhonov et al., unpublished). Speciﬁc recognition of furin
cleavage sequences in the basic domain of Tat may be useful fordeveloping molecular tools that inactivate Tat by targeting the
most conserved part of this viral regulatory molecule.
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